Document is current

Any future updates will be listed below

Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors

Crossref DOI link: https://doi.org/10.1186/s13550-014-0038-2

Published Online: 2014-09-10

Published Print: 2014-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark